PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
23707533-1	2013	Neuropeptide Y (NPY) and nuclear factor-kappa B (NF-kappaB) are involved in regulating anorexia elicited by phenylpropanolamine (PPA), a sympathomimetic drug.	Phenylpropanolamine	108-127	neuropeptide Y	Rattus norvegicus	16-19
23845085-5	2013	RESULTS: Cathinone, cathine and norephedrine generally reduced post-translational modifications of intracellular signal transducers in T-lymphocytes, B-lymphocytes, natural killer cells and monocytes, most prominently affecting c-Cbl (pTyr700), ERK1/2 (p-Thr202/p-Tyr204), p38 MAPK (p-Thr180/p-Tyr182) and p53 (both total p53 protein and p-Ser15).	Phenylpropanolamine	32-44	Cbl proto-oncogene	Homo sapiens	228-233
23845085-5	2013	RESULTS: Cathinone, cathine and norephedrine generally reduced post-translational modifications of intracellular signal transducers in T-lymphocytes, B-lymphocytes, natural killer cells and monocytes, most prominently affecting c-Cbl (pTyr700), ERK1/2 (p-Thr202/p-Tyr204), p38 MAPK (p-Thr180/p-Tyr182) and p53 (both total p53 protein and p-Ser15).	Phenylpropanolamine	32-44	mitogen-activated protein kinase 3	Homo sapiens	245-251
23845085-5	2013	RESULTS: Cathinone, cathine and norephedrine generally reduced post-translational modifications of intracellular signal transducers in T-lymphocytes, B-lymphocytes, natural killer cells and monocytes, most prominently affecting c-Cbl (pTyr700), ERK1/2 (p-Thr202/p-Tyr204), p38 MAPK (p-Thr180/p-Tyr182) and p53 (both total p53 protein and p-Ser15).	Phenylpropanolamine	32-44	mitogen-activated protein kinase 1	Homo sapiens	273-276
23845085-5	2013	RESULTS: Cathinone, cathine and norephedrine generally reduced post-translational modifications of intracellular signal transducers in T-lymphocytes, B-lymphocytes, natural killer cells and monocytes, most prominently affecting c-Cbl (pTyr700), ERK1/2 (p-Thr202/p-Tyr204), p38 MAPK (p-Thr180/p-Tyr182) and p53 (both total p53 protein and p-Ser15).	Phenylpropanolamine	32-44	tumor protein p53	Homo sapiens	306-309
23845085-5	2013	RESULTS: Cathinone, cathine and norephedrine generally reduced post-translational modifications of intracellular signal transducers in T-lymphocytes, B-lymphocytes, natural killer cells and monocytes, most prominently affecting c-Cbl (pTyr700), ERK1/2 (p-Thr202/p-Tyr204), p38 MAPK (p-Thr180/p-Tyr182) and p53 (both total p53 protein and p-Ser15).	Phenylpropanolamine	32-44	tumor protein p53	Homo sapiens	322-325
23845085-10	2013	Cathinone, cathine and norephedrine reduced phosphorylation of c-Cbl, ERK1/2, p38 MAPK and p53(Ser15), and norephedrine induced T-lymphocyte proliferation.	Phenylpropanolamine	23-35	Cbl proto-oncogene	Homo sapiens	63-68
23845085-10	2013	Cathinone, cathine and norephedrine reduced phosphorylation of c-Cbl, ERK1/2, p38 MAPK and p53(Ser15), and norephedrine induced T-lymphocyte proliferation.	Phenylpropanolamine	23-35	mitogen-activated protein kinase 3	Homo sapiens	70-76
23845085-10	2013	Cathinone, cathine and norephedrine reduced phosphorylation of c-Cbl, ERK1/2, p38 MAPK and p53(Ser15), and norephedrine induced T-lymphocyte proliferation.	Phenylpropanolamine	23-35	mitogen-activated protein kinase 1	Homo sapiens	78-81
23845085-10	2013	Cathinone, cathine and norephedrine reduced phosphorylation of c-Cbl, ERK1/2, p38 MAPK and p53(Ser15), and norephedrine induced T-lymphocyte proliferation.	Phenylpropanolamine	23-35	tumor protein p53	Homo sapiens	91-94
23707533-1	2013	Neuropeptide Y (NPY) and nuclear factor-kappa B (NF-kappaB) are involved in regulating anorexia elicited by phenylpropanolamine (PPA), a sympathomimetic drug.	Phenylpropanolamine	129-132	neuropeptide Y	Rattus norvegicus	16-19
21989786-1	2012	It has been reported that oxidative stress, antioxidants, and neuropeptide Y (NPY) are involved in regulating the feeding behavior of phenylpropanolamine (PPA), a sympathomimetic drug.	Phenylpropanolamine	134-153	neuropeptide Y	Rattus norvegicus	62-76
23123211-3	2013	In the cells treated with norephedrine also, an autophagic marker LC3 was converted to its LC3-II activated form, suggesting the induction of autophagy.	Phenylpropanolamine	26-38	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	66-69
23123211-3	2013	In the cells treated with norephedrine also, an autophagic marker LC3 was converted to its LC3-II activated form, suggesting the induction of autophagy.	Phenylpropanolamine	26-38	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	91-94
23123211-5	2013	An autophagic flux assay using tfLC3 (mRFP-GFP-LC3) indicated the formation of autophagosomes and autolysosomes by norephedrine stimulation at an early timepoint (~3 h).	Phenylpropanolamine	115-127	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	33-36
23052195-0	2013	Neuropeptide Y Y1 receptor knockdown can modify glutathione peroxidase and c-AMP response element-binding protein in phenylpropanolamine-treated rats.	Phenylpropanolamine	117-136	neuropeptide Y	Rattus norvegicus	0-14
23052195-0	2013	Neuropeptide Y Y1 receptor knockdown can modify glutathione peroxidase and c-AMP response element-binding protein in phenylpropanolamine-treated rats.	Phenylpropanolamine	117-136	cAMP responsive element binding protein 1	Rattus norvegicus	75-113
23052195-1	2013	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and c-AMP response element-binding protein (CREB) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression.	Phenylpropanolamine	148-167	neuropeptide Y	Rattus norvegicus	49-63
23052195-1	2013	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and c-AMP response element-binding protein (CREB) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression.	Phenylpropanolamine	148-167	neuropeptide Y	Rattus norvegicus	65-68
23052195-1	2013	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and c-AMP response element-binding protein (CREB) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression.	Phenylpropanolamine	148-167	cAMP responsive element binding protein 1	Rattus norvegicus	75-113
23052195-1	2013	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and c-AMP response element-binding protein (CREB) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression.	Phenylpropanolamine	148-167	cAMP responsive element binding protein 1	Rattus norvegicus	115-119
23052195-1	2013	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and c-AMP response element-binding protein (CREB) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression.	Phenylpropanolamine	169-172	neuropeptide Y	Rattus norvegicus	49-63
23052195-1	2013	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and c-AMP response element-binding protein (CREB) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression.	Phenylpropanolamine	169-172	neuropeptide Y	Rattus norvegicus	65-68
23052195-1	2013	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and c-AMP response element-binding protein (CREB) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression.	Phenylpropanolamine	169-172	cAMP responsive element binding protein 1	Rattus norvegicus	75-113
23052195-1	2013	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and c-AMP response element-binding protein (CREB) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression.	Phenylpropanolamine	169-172	cAMP responsive element binding protein 1	Rattus norvegicus	115-119
23052195-8	2013	These results suggest that Y1R participates in the reciprocal regulation of NPY, GP, and CREB in the hypothalamus during PPA treatment in conscious rats.	Phenylpropanolamine	121-124	neuropeptide Y	Rattus norvegicus	76-79
23052195-8	2013	These results suggest that Y1R participates in the reciprocal regulation of NPY, GP, and CREB in the hypothalamus during PPA treatment in conscious rats.	Phenylpropanolamine	121-124	cAMP responsive element binding protein 1	Rattus norvegicus	89-93
23179670-0	2013	The identification of neuropeptide Y receptor subtype involved in phenylpropanolamine-induced increase in oxidative stress and appetite suppression.	Phenylpropanolamine	66-85	neuropeptide Y	Rattus norvegicus	22-36
23179670-1	2013	Hypothalamic neuropeptide Y (NPY) and superoxide dismutase (SOD) have been reported to participate in the regulation of appetite-suppressing effect of phenylpropanolamine (PPA), a sympathomimetic agent.	Phenylpropanolamine	151-170	neuropeptide Y	Rattus norvegicus	0-33
23179670-1	2013	Hypothalamic neuropeptide Y (NPY) and superoxide dismutase (SOD) have been reported to participate in the regulation of appetite-suppressing effect of phenylpropanolamine (PPA), a sympathomimetic agent.	Phenylpropanolamine	172-175	neuropeptide Y	Rattus norvegicus	0-33
21989786-1	2012	It has been reported that oxidative stress, antioxidants, and neuropeptide Y (NPY) are involved in regulating the feeding behavior of phenylpropanolamine (PPA), a sympathomimetic drug.	Phenylpropanolamine	134-153	neuropeptide Y	Rattus norvegicus	78-81
21989786-1	2012	It has been reported that oxidative stress, antioxidants, and neuropeptide Y (NPY) are involved in regulating the feeding behavior of phenylpropanolamine (PPA), a sympathomimetic drug.	Phenylpropanolamine	155-158	neuropeptide Y	Rattus norvegicus	62-76
21989786-1	2012	It has been reported that oxidative stress, antioxidants, and neuropeptide Y (NPY) are involved in regulating the feeding behavior of phenylpropanolamine (PPA), a sympathomimetic drug.	Phenylpropanolamine	155-158	neuropeptide Y	Rattus norvegicus	78-81
21989786-8	2012	It is suggested that hypothalamic NF-kappaB participates in the reciprocal regulation of NPY and antioxidants, which mediated the appetite-suppressing effect of PPA.	Phenylpropanolamine	161-164	neuropeptide Y	Rattus norvegicus	89-92
21519742-3	2011	Prolamines were determined in the quinua and lupin flours by the ELISA test and the HPLC technique was used in both products obtained called "sweet mix" and "dessert mix", to define the quantity of amino acids with the purpose of providing around the 15% of the proteins required in the day.	Phenylpropanolamine	0-10	5'-nucleotidase, cytosolic IIIA	Homo sapiens	45-50
21453188-10	2011	CONCLUSION: Results suggest that ROS-RE/POMC- and NPY-containing neurons function reciprocally in regulating both the anorectic and tolerant effects of PPA, while aPKC is upstream of these regulators.	Phenylpropanolamine	152-155	proopiomelanocortin	Rattus norvegicus	40-44
21453188-10	2011	CONCLUSION: Results suggest that ROS-RE/POMC- and NPY-containing neurons function reciprocally in regulating both the anorectic and tolerant effects of PPA, while aPKC is upstream of these regulators.	Phenylpropanolamine	152-155	neuropeptide Y	Rattus norvegicus	50-53
17684035-7	2007	Results also showed that PKA knock-down could block PPA-induced anorexia as well as restore NPY mRNA level, indicating the involvement of PKA signaling in the regulation of NPY gene expression.	Phenylpropanolamine	52-55	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	25-28
19183253-0	2009	Roles of protein kinase Calpha isozyme in the regulation of oxidative stress and neuropeptide Y gene expression in phenylpropanolamine-mediated appetite suppression.	Phenylpropanolamine	115-134	neuropeptide Y	Rattus norvegicus	81-95
19183253-2	2009	Although regulation of NPY expression has been reported to contribute to the appetite-suppressing effect of phenylpropanolamine (PPA), it is still unknown if protein kinase C (PKC) is involved in this effect.	Phenylpropanolamine	108-127	neuropeptide Y	Rattus norvegicus	23-26
19183253-2	2009	Although regulation of NPY expression has been reported to contribute to the appetite-suppressing effect of phenylpropanolamine (PPA), it is still unknown if protein kinase C (PKC) is involved in this effect.	Phenylpropanolamine	129-132	neuropeptide Y	Rattus norvegicus	23-26
17868324-0	2008	Interrupting activator protein-1 signaling in conscious rats can modify neuropeptide Y gene expression and feeding behavior of phenylpropanolamine.	Phenylpropanolamine	127-146	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	13-32
17868324-1	2008	The mechanism for phenylpropanolamine (PPA)-induced anorexia has been attributed to its inhibitory action on hypothalamic neuropeptide Y (NPY), an orexigenic agent abundant in the brain.	Phenylpropanolamine	18-37	neuropeptide Y	Rattus norvegicus	122-136
17868324-1	2008	The mechanism for phenylpropanolamine (PPA)-induced anorexia has been attributed to its inhibitory action on hypothalamic neuropeptide Y (NPY), an orexigenic agent abundant in the brain.	Phenylpropanolamine	18-37	neuropeptide Y	Rattus norvegicus	138-141
17868324-1	2008	The mechanism for phenylpropanolamine (PPA)-induced anorexia has been attributed to its inhibitory action on hypothalamic neuropeptide Y (NPY), an orexigenic agent abundant in the brain.	Phenylpropanolamine	39-42	neuropeptide Y	Rattus norvegicus	122-136
17868324-1	2008	The mechanism for phenylpropanolamine (PPA)-induced anorexia has been attributed to its inhibitory action on hypothalamic neuropeptide Y (NPY), an orexigenic agent abundant in the brain.	Phenylpropanolamine	39-42	neuropeptide Y	Rattus norvegicus	138-141
20533995-1	2010	Hypothalamic neuropeptide Y (NPY) has been reported to involve in regulating behavioral response of phenylpropanolamine (PPA), a sympathomimetic agent.	Phenylpropanolamine	100-119	neuropeptide Y	Rattus norvegicus	0-33
20533995-1	2010	Hypothalamic neuropeptide Y (NPY) has been reported to involve in regulating behavioral response of phenylpropanolamine (PPA), a sympathomimetic agent.	Phenylpropanolamine	121-124	neuropeptide Y	Rattus norvegicus	0-33
20533995-6	2010	Results showed that PKCdelta and CAT increased during PPA treatment, which were concomitant with decreases in NPY content and food intake, while the change of NOS was expressed differently.	Phenylpropanolamine	54-57	catalase	Rattus norvegicus	33-36
20533995-6	2010	Results showed that PKCdelta and CAT increased during PPA treatment, which were concomitant with decreases in NPY content and food intake, while the change of NOS was expressed differently.	Phenylpropanolamine	54-57	neuropeptide Y	Rattus norvegicus	110-113
18221372-1	2008	The appetite-suppressing effect of phenylpropanolamine (PPA) has been attributed to its inhibitory action on neuropeptide Y (NPY), an appetite stimulant.	Phenylpropanolamine	35-54	neuropeptide Y	Rattus norvegicus	109-123
18221372-1	2008	The appetite-suppressing effect of phenylpropanolamine (PPA) has been attributed to its inhibitory action on neuropeptide Y (NPY), an appetite stimulant.	Phenylpropanolamine	35-54	neuropeptide Y	Rattus norvegicus	125-128
18221372-1	2008	The appetite-suppressing effect of phenylpropanolamine (PPA) has been attributed to its inhibitory action on neuropeptide Y (NPY), an appetite stimulant.	Phenylpropanolamine	56-59	neuropeptide Y	Rattus norvegicus	109-123
18221372-1	2008	The appetite-suppressing effect of phenylpropanolamine (PPA) has been attributed to its inhibitory action on neuropeptide Y (NPY), an appetite stimulant.	Phenylpropanolamine	56-59	neuropeptide Y	Rattus norvegicus	125-128
18221372-9	2008	Furthermore, infusions of CREB antisense oligonucleotide (or missense control) into cerebroventricle were performed at 1 h before daily PPA treatment in free-moving rats, and results showed that CREB knockdown could block PPA-induced anorexia and modify NPY and SOD-2 mRNA content toward normal.	Phenylpropanolamine	136-139	cAMP responsive element binding protein 1	Rattus norvegicus	195-199
18221372-9	2008	Furthermore, infusions of CREB antisense oligonucleotide (or missense control) into cerebroventricle were performed at 1 h before daily PPA treatment in free-moving rats, and results showed that CREB knockdown could block PPA-induced anorexia and modify NPY and SOD-2 mRNA content toward normal.	Phenylpropanolamine	222-225	cAMP responsive element binding protein 1	Rattus norvegicus	26-30
18221372-9	2008	Furthermore, infusions of CREB antisense oligonucleotide (or missense control) into cerebroventricle were performed at 1 h before daily PPA treatment in free-moving rats, and results showed that CREB knockdown could block PPA-induced anorexia and modify NPY and SOD-2 mRNA content toward normal.	Phenylpropanolamine	222-225	cAMP responsive element binding protein 1	Rattus norvegicus	195-199
17684035-0	2007	Transcript of protein kinase A knock-down modulates feeding behavior and neuropeptide Y gene expression in phenylpropanolamine-treated rats.	Phenylpropanolamine	107-126	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	14-30
17684035-0	2007	Transcript of protein kinase A knock-down modulates feeding behavior and neuropeptide Y gene expression in phenylpropanolamine-treated rats.	Phenylpropanolamine	107-126	neuropeptide Y	Rattus norvegicus	73-87
17684035-1	2007	Neuropeptide Y (NPY) is an appetite-controlling neuromodulator that contributes to the appetite-suppressing effect of phenylpropanolamine (PPA).	Phenylpropanolamine	118-137	neuropeptide Y	Rattus norvegicus	0-14
17684035-1	2007	Neuropeptide Y (NPY) is an appetite-controlling neuromodulator that contributes to the appetite-suppressing effect of phenylpropanolamine (PPA).	Phenylpropanolamine	118-137	neuropeptide Y	Rattus norvegicus	16-19
17684035-1	2007	Neuropeptide Y (NPY) is an appetite-controlling neuromodulator that contributes to the appetite-suppressing effect of phenylpropanolamine (PPA).	Phenylpropanolamine	139-142	neuropeptide Y	Rattus norvegicus	0-14
17684035-1	2007	Neuropeptide Y (NPY) is an appetite-controlling neuromodulator that contributes to the appetite-suppressing effect of phenylpropanolamine (PPA).	Phenylpropanolamine	139-142	neuropeptide Y	Rattus norvegicus	16-19
17907825-0	2007	Roles of central catecholamine and hypothalamic neuropeptide Y genome in the development of tolerance to phenylpropanolamine-mediated appetite suppression.	Phenylpropanolamine	105-124	neuropeptide Y	Homo sapiens	48-62
17907825-5	2007	Moreover, results also revealed that the alteration in NPY messenger RNA level coincided with the change of feeding behavior during PPA treatment and that infusions of NPY antisense oligonucleotide into the cerebroventricle abolished the effect of PPA tolerance.	Phenylpropanolamine	132-135	neuropeptide Y	Homo sapiens	55-58
17907825-5	2007	Moreover, results also revealed that the alteration in NPY messenger RNA level coincided with the change of feeding behavior during PPA treatment and that infusions of NPY antisense oligonucleotide into the cerebroventricle abolished the effect of PPA tolerance.	Phenylpropanolamine	132-135	neuropeptide Y	Homo sapiens	168-171
17907825-5	2007	Moreover, results also revealed that the alteration in NPY messenger RNA level coincided with the change of feeding behavior during PPA treatment and that infusions of NPY antisense oligonucleotide into the cerebroventricle abolished the effect of PPA tolerance.	Phenylpropanolamine	248-251	neuropeptide Y	Homo sapiens	55-58
17907825-5	2007	Moreover, results also revealed that the alteration in NPY messenger RNA level coincided with the change of feeding behavior during PPA treatment and that infusions of NPY antisense oligonucleotide into the cerebroventricle abolished the effect of PPA tolerance.	Phenylpropanolamine	248-251	neuropeptide Y	Homo sapiens	168-171
17907825-6	2007	These findings suggest that cerebral CAT and hypothalamic NPY genome are involved in the development of tolerance to PPA-induced appetite suppression.	Phenylpropanolamine	117-120	neuropeptide Y	Homo sapiens	58-61
17684035-7	2007	Results also showed that PKA knock-down could block PPA-induced anorexia as well as restore NPY mRNA level, indicating the involvement of PKA signaling in the regulation of NPY gene expression.	Phenylpropanolamine	52-55	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	138-141
17684035-7	2007	Results also showed that PKA knock-down could block PPA-induced anorexia as well as restore NPY mRNA level, indicating the involvement of PKA signaling in the regulation of NPY gene expression.	Phenylpropanolamine	52-55	neuropeptide Y	Rattus norvegicus	173-176
17684035-8	2007	It is suggested that hypothalamic PKA signaling may participate in the central regulation of PPA-mediated appetite suppression via the modulation of hypothalamic NPY gene expression.	Phenylpropanolamine	93-96	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	34-37
17684035-9	2007	The present findings reveal that manipulations at the molecular level of PKA or cAMP may allow the development of therapeutic agents to improve the undesirable properties of PPA or other amphetamine-like anorectic drugs.	Phenylpropanolamine	174-177	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	73-76
15944721-10	2005	Phenylpropanolamine increased SBP 5.5 mmHg (95% CI: 3.1-8.0) and DBP 4.1 mmHg (95% CI: 2.2-6.0) with no effect on pulse.	Phenylpropanolamine	0-19	selenium binding protein 1	Homo sapiens	30-33
15829281-2	2005	Various seminal studies have established the precise mechanism of how antigen (prolamine) specific activation of CD4+ mucosal T cells occurs.	Phenylpropanolamine	79-88	CD4 molecule	Homo sapiens	113-116
15244451-1	2004	Zein, the prolamine of corn, has been investigated for its potential as an industrial biopolymer.	Phenylpropanolamine	10-19	zein	Zea mays	0-4
15608085-11	2005	In mesenteric arteries, constriction to phenylpropanolamine was not affected by the selective alpha2-adrenergic antagonist, rauwolscine (10(-7) M) but was abolished by the selective alpha1-adrenergic antagonist, prazosin (3 x 10(-7) M).	Phenylpropanolamine	40-59	adrenoceptor alpha 1D	Homo sapiens	182-188
15608085-14	2005	At low concentrations, it constricts blood vessels that express functional alpha2-adrenoceptors, whereas at much higher concentrations, phenylpropanolamine also activates vascular alpha1-adrenoceptors.	Phenylpropanolamine	136-155	adrenoceptor alpha 1D	Homo sapiens	180-186
15572205-6	2004	Results revealed that PPA treatment in rats could decrease both NPY content and mRNA level in the hypothalamus.	Phenylpropanolamine	22-25	neuropeptide Y	Rattus norvegicus	64-67
15572205-7	2004	In addition, the expression of NPY immunoreactivity following PPA treatment was decreased in areas of hypothalamic arcuate nucleus, paraventricular nucleus and periventricular area using immunohistochemical staining, suggesting an involvement of NPYergic pathway in the action of PPA anorexia.	Phenylpropanolamine	62-65	neuropeptide Y	Rattus norvegicus	31-34
15572205-7	2004	In addition, the expression of NPY immunoreactivity following PPA treatment was decreased in areas of hypothalamic arcuate nucleus, paraventricular nucleus and periventricular area using immunohistochemical staining, suggesting an involvement of NPYergic pathway in the action of PPA anorexia.	Phenylpropanolamine	280-283	neuropeptide Y	Rattus norvegicus	31-34
15163201-5	2004	Many of the compounds that were highly selective in vitro for the alpha(1A)-AR subtype were also more uroselective in vivo for increasing IUP over MAP than the nonselective alpha(1)-agonists phenylpropanolamine (PPA) (1) and ST-1059 (2, the active metabolite of midodrine), supporting the hypothesis that greater alpha(1A) selectivity would reduce cardiovascular side effects.	Phenylpropanolamine	212-215	adrenoceptor alpha 1A	Rattus norvegicus	76-78
1914371-6	1991	This effect could not be explained by any pharmacokinetic interaction between the two drugs and occurred even though phenylpropanolamine attenuated the epinephrine and renin response to caffeine.	Phenylpropanolamine	117-136	renin	Homo sapiens	168-173
15066944-7	2004	However, when ingested with 16 oz of room temperature tap water, phenylpropanolamine increased SBP by 82+/-2 mm Hg.	Phenylpropanolamine	65-84	nuclear RNA export factor 1	Homo sapiens	54-57
15096055-1	2004	Opaque-2 (O2) is a plant bZIP transcription factor that regulates the expression of alpha and beta prolamines, the main storage proteins in seeds of cereals such as maize and Coix.	Phenylpropanolamine	99-109	regulatory protein opaque-2	Zea mays	10-12
12873745-7	2003	These findings suggested that both subtypes of alpha1 adrenoceptor and D(1) receptor were involved in the anorectic action of PPA.	Phenylpropanolamine	126-129	dopamine receptor D1	Mus musculus	71-84
12649305-14	2003	The alpha-adrenergic agonist phenylpropanolamine (PPA; 1 mg/kg i.v.)	Phenylpropanolamine	29-48	inorganic pyrophosphatase	Cavia porcellus	50-56
12323066-2	2002	A biaryldioxanone auxiliary set the anti C11-12 hydroxy-methoxy functionality and a methylglycolate auxiliary based on norephedrine was used for the syn C6-7 methoxy-urethane.	Phenylpropanolamine	119-131	synemin	Homo sapiens	149-152
12238918-0	2002	N-[3-(1H-imidazol-4-ylmethyl)phenyl]ethanesulfonamide (ABT-866, 1),(1) a novel alpha(1)-adrenoceptor ligand with an enhanced in vitro and in vivo profile relative to phenylpropanolamine and midodrine.	Phenylpropanolamine	166-185	activator of basal transcription 1	Rattus norvegicus	55-65
11327009-1	1998	By using normal-phase HPLC with urea derivative as chiral stationary phase(CSP), the direct separation of racemic norephedrine has been investigated.	Phenylpropanolamine	114-126	DnaJ heat shock protein family (Hsp40) member C5	Homo sapiens	75-78
3172133-5	1988	Although the norephedrines (7 and 8) and the norpseudoephedrines (9 and 10) were poorer ligands for PNMT than were the 2-amino-1-tetralols (13-16), (1R,2S)-(-)-norephedrine (7) showed some activity as a PNMT substrate (Km = 1310 microM, Vmax = 0.22, 100 x Vmax/Km = 0.017).	Phenylpropanolamine	13-26	phenylethanolamine N-methyltransferase	Homo sapiens	100-104
1722692-11	1991	The cardiovascular effects of phenylpropanolamine, including vasoconstriction and an increase in cardiac performance, are consistent with its alpha- and beta 1-adrenoceptor agonist action.	Phenylpropanolamine	30-49	adrenoceptor beta 1	Homo sapiens	142-172
2907582-0	1988	Beta 2-adrenoceptor influences on the alpha 1- and alpha 2-mediated vasoconstriction induced by phenylpropanolamine and its two component enantiomers in the pithed rat.	Phenylpropanolamine	96-115	adrenoceptor beta 2	Rattus norvegicus	0-19
1894758-8	1991	The study supports the idea that phenylpropanolamine as both a direct (at alpha -1 and alpha-2 receptors) and an indirect sympathomimetic agent.	Phenylpropanolamine	33-52	adrenoceptor alpha 1D	Homo sapiens	74-82
3310024-3	1987	Phenylpropanolamine (15, 25 and 35 mg/kg IP) significantly reduced food intake in a dose-related fashion at the 1 hr and 3 hr time intervals in the food deprivation-, insulin- and 2-deoxy glucose-induced hyperphagic models.	Phenylpropanolamine	0-19	insulin 2	Rattus norvegicus	167-181
3987172-11	1985	This is probably because PPA has less beta 2 activity than does norepinephrine.	Phenylpropanolamine	25-28	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	38-44
3961266-0	1986	Inhibition of monoamine oxidase activity by phenylpropanolamine, an anorectic agent.	Phenylpropanolamine	44-63	monoamine oxidase A	Rattus norvegicus	14-31
3961266-3	1986	PPA was found to inhibit both human brain and rat liver mitochondrial MAO activities in vitro, i.e. Ki"s were 150 microM and 800 microM with respect to serotonin (Type A substrate) and beta-phenylethylamine (Type B substrate).	Phenylpropanolamine	0-3	monoamine oxidase A	Rattus norvegicus	70-73
3961266-5	1986	PPA can also inhibit MAO-A activity in vivo at relatively high dose (50 mg/kg, i.p.	Phenylpropanolamine	0-3	monoamine oxidase A	Rattus norvegicus	21-26
3961266-6	1986	), which was determined from an observation that PPA can protect MAO from the irreversible MAO inhibitor clorgyline.	Phenylpropanolamine	49-52	monoamine oxidase A	Rattus norvegicus	65-68
3961266-6	1986	), which was determined from an observation that PPA can protect MAO from the irreversible MAO inhibitor clorgyline.	Phenylpropanolamine	49-52	monoamine oxidase A	Rattus norvegicus	91-94
27862969-0	2017	Mediation of oxidative stress in hypothalamic ghrelin-associated appetite control in rats treated with phenylpropanolamine.	Phenylpropanolamine	103-122	ghrelin and obestatin prepropeptide	Rattus norvegicus	46-53
16661153-1	1980	Zein, the prolamine fraction of maize, is localized in the endosperm in membrane-bound structures called protein bodies, which have polyribosomes on their surfaces.	Phenylpropanolamine	10-19	zein	Zea mays	0-4
31577462-5	2021	Median CRT 1-week post-treatment was lower among subjects who developed PPA (p-value = 0.03).	Phenylpropanolamine	72-75	hyaluronan and proteoglycan link protein 1	Homo sapiens	7-12
32896521-7	2020	Juvenile PPA pretreatment facilitated the rise in NAC glutamate elicited by dopamine, norepinephrine and glutamate transporter inhibitors and blunted mGlu2/3 inhibition of glutamate release in this region.	Phenylpropanolamine	9-12	glutamate receptor, metabotropic 3	Mus musculus	150-157
32247179-1	2020	Zein, a class of prolamine proteins extracted from maize, is extensively used in the food and pharmaceutical industries.	Phenylpropanolamine	17-26	zein	Zea mays	0-4
6818635-3	1980	The four wheat prolamine groups (alpha, beta, gamma and omega gliadins), visible in electrophoresis at acid pH, have been isolated and their toxicities compared by observing the morphological changes in intestinal biopsies cultured in vitro when peptic-tryptic digests of the studied proteins were added to the culture medium.	Phenylpropanolamine	15-24	Gli-G1	Triticum aestivum	32-70
27862969-4	2017	Results showed that both food intake and the expression of NPY and ghrelin/AG/GOAT/GHSR1a decreased in response to PPA treatment with maximum decrease on Day 2 of the treatment.	Phenylpropanolamine	115-118	pro-neuropeptide Y	Capra hircus	59-62
27862969-4	2017	Results showed that both food intake and the expression of NPY and ghrelin/AG/GOAT/GHSR1a decreased in response to PPA treatment with maximum decrease on Day 2 of the treatment.	Phenylpropanolamine	115-118	ghrelin and obestatin prepropeptide	Rattus norvegicus	67-74
27862969-7	2017	We suggest that hypothalamic ghrelin signaling system, with the help of antioxidants, may participate in NPY/CART-mediated appetite control in PPA-treated rats.	Phenylpropanolamine	143-146	ghrelin and obestatin prepropeptide	Rattus norvegicus	29-36
27862969-2	2017	This study explored whether hypothalamic antioxidants participated in hypothalamic ghrelin system-associated appetite control in PPA-treated rats.	Phenylpropanolamine	129-132	ghrelin and obestatin prepropeptide	Rattus norvegicus	83-90
27862969-7	2017	We suggest that hypothalamic ghrelin signaling system, with the help of antioxidants, may participate in NPY/CART-mediated appetite control in PPA-treated rats.	Phenylpropanolamine	143-146	neuropeptide Y	Rattus norvegicus	105-108
27862969-7	2017	We suggest that hypothalamic ghrelin signaling system, with the help of antioxidants, may participate in NPY/CART-mediated appetite control in PPA-treated rats.	Phenylpropanolamine	143-146	CART prepropeptide	Rattus norvegicus	109-113
24792324-7	2015	Moreover, cerebral STAT3 knockdown modified PPA-induced anorexia and antioxidants, POMC, and NPY expression.	Phenylpropanolamine	44-47	signal transducer and activator of transcription 3	Rattus norvegicus	19-24
24792324-7	2015	Moreover, cerebral STAT3 knockdown modified PPA-induced anorexia and antioxidants, POMC, and NPY expression.	Phenylpropanolamine	44-47	proopiomelanocortin	Rattus norvegicus	83-87
24792324-7	2015	Moreover, cerebral STAT3 knockdown modified PPA-induced anorexia and antioxidants, POMC, and NPY expression.	Phenylpropanolamine	44-47	neuropeptide Y	Rattus norvegicus	93-96
27621432-8	2016	When the promoters of these genes were analyzed, we found a prolamine box and an O2 box that can be additively transactivated by PBF and O2.	Phenylpropanolamine	60-69	dof zinc finger protein PBF	Zea mays	129-132
27024953-2	2015	IgE mediated gluten allergy can be induced either by gluten as an in- gredient in foods or wheat prolamines present in the air.	Phenylpropanolamine	97-107	immunoglobulin heavy constant epsilon	Homo sapiens	0-3